QuiremSpheres®

HCC

SIRT

QuiremSpheres® treatment of a 77-year-old male patient with hepatocellular carcinoma

Physician: Prof. Dr. Ralf-Thorsten Hoffmann (IR) and Dr. Klaus Zoephel (NM)
Location: University Hospital Dresden, Germany

PATIENT

A 77-year-old male patient with a history of hepatocellular carcinoma (HCC) was first diagnosed with large HCC in the right liver lobe (LL) without cirrhosis, and treated by embolization of the right portal vein and chemoembolization of the right LL. Follow-up after 18 months showed multifocal (n>10) HCC in the remnant liver. Patient was in good shape (ECOG 0) and liver enzymes were in normal range.



Primovist® enhanced pre-treatment MRI

TREATMENT PLANNING

Based on the health status and treatment history of the patient, the multidisciplinary tumor board decided to treat him with SIRT. During work-up, the patient showed no clinically significant lung shunting (0.17%). A dose of 60 Gy was planned on the remnant liver volume (1335 cc) with a 30% reduction on the calculated activity as a safety precaution, since the patient has no right LL.



SPECT-based dose distribution

TREATMENT

QuiremSpheres® microspheres with a total net activity of 3.2 GBq were injected via a microcatheter in the left hepatic artery.

TREATMENT VERIFICATION

The distribution of microspheres was evaluated using SPECT and quantitative MR imaging in the days following the procedure. The images were converted into 3D dose distribution using Q-Suite™. The two targeted volumes shown in the images on the right received a mean dose of 150 Gy (left tumor) and 80 Gy (right tumor). The nontargeted liver volume received a mean dose of 21 Gy.



4 months follow-up post treatment anatomical MRI

OUTCOME

The treatment was well tolerated. At 4 months follow-up, excellent tumor response was seen on MR imaging.

QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark. QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale. QuiremSpheres® is not approved in Canada. Terumo is the exclusive distributor for QuiremSpheres®

https://www.terumo-europe.com/en-emea/Treat-liver-cancer-with-Terumo-2018

byagency

PUSHING BOUNDARIES

TERUMO INTERVENTIONAL SYSTEMS